It is estimated that there were 26,444 people living with HIV in Australia in 2016. Of these an estimated 23,648 (89%) were diagnosed, 22,465 (95% of those diagnosed) were retained in care, 20,440 (86% of those diagnosed) were receiving antiretroviral therapy, and 19,013 (93% of those on antiretroviral therapy) had achieved viral suppression1.
Based on 46 cases, the age standardised rate of HIV notification in 2016 among Aboriginal and Torres Strait Islander peoples was more than double the rate in the Australian‑born non‑Indigenous population (6.4 versus 2.9 per 100 000)1.
The prevalence of HIV among injecting drug users in Australia is very low, approximately 1.4%1.
Mother-to-child transmission is rare in Australia.
The advances in antiretroviral (ARV) treatment have meant that HIV is now considered a chronic condition. Antiretroviral (ARV) treatments have evolved and are now effective, simple and cause fewer side effects.
Antiretrovirals work to inhibit viral replication. The goal of ARV treatment is to achieve an undetectable viral load in plasma.
Although plasma is normally tested for viral activity, a reduction also occurs in other body fluids associated with HIV transmission (notably semen and vaginal fluid).
Immediate initiation of HIV treatment is clinically superior to deferred treatment among people with HIV infection, regardless of CD4 count or stage of disease.
HIV treatment is highly effective in the prevention of the sexual transmission of HIV.
Pre-exposure prophylaxis (PrEP) is a highly effective tool for preventing HIV infection in high risk HIV negative individuals.
1. The Kirby Institute HIV, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2017. The Kirby Institute, the University of New South Wales, Sydney